Market Size of Endocrinology Drugs Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 101.60 Billion |
| Market Size (2029) | USD 136.60 Billion |
| CAGR (2024 - 2029) | 6.09 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Endocrinology Drugs Market Analysis
The Endocrinology Drugs Market size is estimated at USD 101.60 billion in 2024, and is expected to reach USD 136.60 billion by 2029, growing at a CAGR of 6.09% during the forecast period (2024-2029).
- The major factors driving the growth of the market include an increase in the prevalence of endocrine disorders, a rising adolescent population with endocrine disorders, and extensive research and development. An increase in endocrine disorders, specifically diabetes, is one of the major factors driving the growth of the endocrinology drug market.
- According to the International Diabetic Foundation (IDF) 2022 update, approximately 537 million adults (20-79 years) had diabetes in 2022. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the rise in diabetes cases globally will likely increase the demand for anti-diabetic drugs, fueling the endocrinology drugs market growth during the forecast period.
- Moreover, the increase in the development of endocrine drugs and the rise in product launches by the major players are expected to boost market growth. For instance, in December 2022, Glenmark Pharma launched a combination drug for diabetic patients. This fixed-dose combination offers patients with type 2 diabetes the convenience of once-daily dosing to improve their glycemic control. It launched under the brand name Zita-PioMet and contained teneligliptin (20 mg), pioglitazone (15 mg), and metformin (500 mg/1,000 mg) in a sustained release (SR) formulation.
- Similarly, in December 2022, Hikma Pharmaceuticals PLC launched Levothyroxine Sodium Injection in the United States. The product is available in ready-to-use vials in a 100 mcg/mL dose. Levothyroxine Sodium is an important medicine used in hospitals to treat myxedema coma. Also, the rising adolescent population with endocrine disorders is expected to propel the endocrinology drugs market over the forecast period. Extensive research and development on endocrine drugs, like new drug delivery systems, novel dosage forms, and formulations, are expected to increase the usage of the drugs, thus augmenting the market growth.
- Thus, considering the rise in endocrine diseases and the development of endocrine drugs, the endocrinology drugs market is expected to witness significant growth over the forecast period. However, the stringent regulatory framework for endocrinology drugs marketing and approvals is expected to restrain the market growth.
Endocrinology Drugs Industry Segmentation
As per the scope of the report, endocrinology is the branch of physiology and medicine concerned with endocrine glands and hormones. The endocrine drugs used in treating disorders of the endocrine system include the glands and organs that make hormones. These disorders include diabetes, infertility, and thyroid, adrenal, and pituitary gland problems.
The endocrinology drugs market is segmented by therapy area, distribution channel, and geography. By therapy area, the market is segmented as adrenal insufficiency, diabetes, thyroid hormone disorder, and other therapy areas. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Therapy Area | |
| Adrenal Insufficiency | |
| Diabetes | |
| Thyroid Hormone Disorder | |
| Other Therapy Areas |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Endocrinology Drugs Market Size Summary
The endocrinology drugs market is poised for substantial growth over the forecast period, driven by an increasing prevalence of endocrine disorders, particularly diabetes, and a rising adolescent population affected by these conditions. The market is experiencing a surge in research and development activities, leading to the development and launch of new endocrine drugs. This is further supported by strategic initiatives from major players, such as product launches and collaborations, which are expected to enhance market dynamics. The demand for anti-diabetic drugs, in particular, is anticipated to rise significantly due to the global increase in diabetes cases, thereby propelling the market forward. However, the market's growth may be tempered by the stringent regulatory framework governing the marketing and approval of endocrinology drugs.
The diabetes segment is expected to capture a significant share of the endocrinology drugs market, fueled by the high prevalence of diabetes and increased investment in diabetic drug research and development. North America is projected to hold a substantial market share, supported by a robust healthcare infrastructure, a high incidence of endocrine diseases, and ongoing research funding. The market is characterized by its fragmented nature, with several global companies, including AbbVie Inc., AstraZeneca PLC, and Novo Nordisk A/S, actively participating. Strategic activities such as product launches and acquisitions are likely to further drive market growth, as evidenced by recent developments in the sector.
Endocrinology Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increase in the Prevalence of Endocrine Disorders
-
1.2.2 Extensive Research and Development Activities and Rise in Product Launch
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Framework
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Therapy Area
-
2.1.1 Adrenal Insufficiency
-
2.1.2 Diabetes
-
2.1.3 Thyroid Hormone Disorder
-
2.1.4 Other Therapy Areas
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Online Pharmacies
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Endocrinology Drugs Market Size FAQs
How big is the Endocrinology Drugs Market?
The Endocrinology Drugs Market size is expected to reach USD 101.60 billion in 2024 and grow at a CAGR of 6.09% to reach USD 136.60 billion by 2029.
What is the current Endocrinology Drugs Market size?
In 2024, the Endocrinology Drugs Market size is expected to reach USD 101.60 billion.
